

At page 2, line 33, please delete "-erbB2" and substitute therefore --c-erbB2--.

At page 3, line 19, please delete "10:M.." and substitute therefore --10 M.--.

At page 40, line 21 please delete "REDLK" and substitute therefore --REDLK
(SEQ ID NO:5)--.

At page 40, line 22 please delete "REDL, RDEL, or KDEL," and substitute
therefore --REDL (SEQ ID NO:6), RDEL (SEQ ID NO:7), or KDEL (SEQ ID NO:8),--.

B² At page 69, line 28, please delete "Herceptin" and substitute therefore --
Herceptin).--

At page 69, line 29, please delete the blank line.

Please cancel the present paper copy of the "SEQUENCE LISTING", pages 1-7,
and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page
numbers 1 to 6 at the end of the application.

In the Claims.

Please cancel claims ~~2~~, 23-33, and 45-52.

Please amend claims 1, 4, 12, 13, 14, 15, 16, 17, 21, 22, 39, 43, 44, 53, and 54 as
follows:

7502 C1
B² 1. (Once amended) A[n] single chain antibody that specifically binds to a c-
erbB2 receptor, that is cross reactive with F5 (SEQ ID NO:1) or C1 (SEQ ID NO:2) at c-erbB2,
and that is an internalizing antibody [epitope bound by F5 or C1].

B⁵ 4. (Once amended) The antibody of claim 1, wherein said antibody shares at
least 70% sequence identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2
and wherein said antibody has a binding affinity for c-erbB2 on cells of at least 10 mM.

Sub D17
B⁶ 12. (Once amended) The antibody of claim 11, wherein said antibody
[has]comprises three complementarity determining regions of the amino acid sequence of SEQ
ID NO: 1.